These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7579490)
21. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211 [TBL] [Abstract][Full Text] [Related]
22. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101 [TBL] [Abstract][Full Text] [Related]
23. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Layfield LJ; Lewis C Anal Quant Cytol Histol; 2007 Aug; 29(4):239-43. PubMed ID: 17879632 [TBL] [Abstract][Full Text] [Related]
24. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis. Schmitt FC; Figueiredo P; Lacerda M Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939 [TBL] [Abstract][Full Text] [Related]
25. Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast. Menezes MV; Cestari AL; Almeida O; Alvarenga M; Pinto GA; Gurgel MS; Souza GA; Zeferino LC Sao Paulo Med J; 2006 May; 124(3):121-4. PubMed ID: 17119686 [TBL] [Abstract][Full Text] [Related]
26. The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Jeffrey SS; Pollack JR Breast Cancer Res; 2003; 5(6):320-8. PubMed ID: 14580250 [TBL] [Abstract][Full Text] [Related]
27. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897 [TBL] [Abstract][Full Text] [Related]
28. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446 [TBL] [Abstract][Full Text] [Related]
29. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast]. Yang M; Xu SP; Ao QL Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534 [TBL] [Abstract][Full Text] [Related]
30. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851 [TBL] [Abstract][Full Text] [Related]
32. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Jimenez RE; Wallis T; Tabasczka P; Visscher DW Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908 [TBL] [Abstract][Full Text] [Related]
33. Flow cytometric DNA analysis of breast cancers with predominance of carcinoma in situ: a comparison of the premalignant and malignant components. Ottesen GL; Christensen IJ; Larsen JK; Hansen B; Andersen AJ Clin Cancer Res; 1995 Aug; 1(8):881-8. PubMed ID: 9816058 [TBL] [Abstract][Full Text] [Related]
34. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients. Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861 [TBL] [Abstract][Full Text] [Related]
35. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998 [TBL] [Abstract][Full Text] [Related]
36. Significance of HER2 protein examination in ductal carcinoma in situ. Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297 [TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
38. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients. Kokate P; Sawaimoon S; Bhatia S; Mandava S Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243 [TBL] [Abstract][Full Text] [Related]
40. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status. Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]